Research & Innovation: Center for Translational Antiviral Research Reports Novel Broad-Spectrum Antiviral Drug Class with Activity Against SARS-CoV-2
Research & Innovation: Center for Translational Antiviral Research Reports Novel Broad-Spectrum Antiviral Drug Class with Activity Against SARS-CoV-2
The COVID-19 pandemic and resurgence of infections by other respiratory RNA viruses such as respiratory syncytial virus (RSV) in children has caused an urgent need for the development of orally available broad-spectrum antiviral therapeutics.
In a study published online on Dec. 2 in Science, researchers in the Institute for Biomedical Sciences at Georgia State University report a new candidate ribonucleoside analog, 4’-fluorouridine (4’-FlU), that has potent antiviral activity against SARS-CoV-2, RSV and other respiratory RNA viruses in cell culture, human organoids and different animal models when administered orally once daily.